Table 3.
Amount of Bevacizumab Delivered into the Eye In Vivo Using Visulex-I: Comparing Standard Ionic Strength (Commercial Bevacizumab Formulation 25 mg/mL) Versus Low Ionic Strength [New Iontophoresis Bevacizumab Formulation (12.5–15.0) mg/mL]; 4 mA, 20 Min (Solution Volume = 500 μL, Contact Area = 2.2 cm2, n = 6)
Formulation | Total amount delivered into the eye (μg) | Amount delivered to retina/choroid (μg) |
---|---|---|
Standard ionic strength | 353 ± 42 | 5 ± 3 |
Low ionic strength | 616 ± 317 | 14 ± 9 |